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Background: Smoking is the principle risk factor for development of chronic obstructive 
pulmonary disease (COPD). Multidrug resistance-associated protein 1 (MRP1) is known to 
protect against toxic compounds and oxidative stress, and might play a role in protection 
against smoke-induced disease progression. We questioned whether MRP1-mediated transport 
is inﬂ  uenced by pulmonary drugs that are commonly prescribed in COPD.
Methods: The immortalized human bronchial epithelial cell line 16HBE14o- was used to ana-
lyze direct in vitro effects of budesonide, formoterol, ipratropium bromide and N-acetylcysteine 
(NAC) on MRP1-mediated transport. Carboxyﬂ  uorescein (CF) was used as a model MRP1 
substrate and was measured with functional ﬂ  ow cytometry.
Results: Formoterol had a minor effect, whereas budesonide concentration-dependently 
decreased CF transport by MRP1. Remarkably, addition of formoterol to the highest concentra-
tion of budesonide increased CF transport. Ipratropium bromide inhibited CF transport at low 
concentrations and tended to increase CF transport at higher levels. NAC increased CF transport 
by MRP1 in a concentration-dependent manner.
Conclusions: Our data suggest that, besides their positive effects on respiratory symptoms, 
budesonide, formoterol, ipratropium bromide, and NAC modulate MRP1 activity in bronchial 
epithelial cells. Further studies are required to assess whether stimulation of MRP1 activity is 
beneﬁ  cial for long-term treatment of COPD.
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Background
Smoking generates oxidative stress in the lungs and is the principal risk factor for 
development of lung cancer and chronic obstructive pulmonary disease (COPD). 
Detoxiﬁ  cation and elimination processes of noxious substances present in cigarette 
smoke are important for both disease prevention and progression, yet little is known 
on these processes in the lung so far. Proteins of the ATP-binding cassette (ABC) 
superfamily such as the multidrug resistance-associated protein 1 (MRP1) may play 
a role, since they protect against oxidative stress and other xenobiotics (Cole et al 
1992). Substrates for MRP1 are glutathione, glucuronate, and sulfate conjugates and 
unconjugated compounds in presence of glutathione, eg, tobacco-speciﬁ  c nitrosamines 
(Leslie et al 2001). Interestingly, the lung and trachea and other tissues with a barrier 
function highly express several ABC transporters (Langmann et al 2003). Especially 
MRP1 is expressed at high levels in human lung tissue (van der Deen et al 2005), 
mainly at the basolateral side of bronchial epithelium (Brechot et al 1998; Scheffer 
et al 2002). We observed that MRP1 expression is diminished in bronchial epithelial 
cells of COPD patients (van der Deen et al 2006) supporting the hypothesis that lower 
functional MRP1 activity is related to COPD development.
So far, COPD is recognized as a relentlessly progressive disease in which 
only smoking cessation reduces the accelerated lung function decline. There is no International Journal of COPD 2008:3(3) 470
van der Deen et al
cure for COPD, yet recently it has been shown that some 
drugs are beneﬁ  cial in the disease management. Inhaled 
corticosteroids and long-acting beta-agonists such as 
budesonide and formoterol reduce the number of exacerba-
tions in COPD (Alsaeedi et al 2002; Sutherland et al 2003) 
and their combination has been shown to be very effective 
(Calverley et al 2003). Treatment of COPD patients with 
the anticholinergic drug ipratropium bromide results in a 
small improvement of lung function, yet does not inﬂ  u-
ence the long-term decline in mild COPD (Anthonisen 
et al 1994). Studies on oral use of the anti-mucolytic drug 
N-acetylcysteine (NAC) have provided contradictory results 
(Stey et al 2000; Decramer et al 2005).
In contrast to the extensive knowledge on chemothera-
peutic drugs as substrates for MRP1, limited data are avail-
able on the effect of pulmonary drugs on the functional 
expression of MRP1 (Hamilton et al 2002). NAC induces 
higher cellular glutathione levels and in this way can protect 
against oxidative stress that may indirectly affect MRP1 
function (Akan et al 2005) but no information is available 
about budesonide, formoterol, and ipratropium bromide in 
this respect.
In the present study, we questioned whether medications 
commonly prescribed to COPD patients affect MRP1-
mediated transport. Therefore, we analyzed the direct in vitro 
effects of budesonide, formoterol, ipratropium bromide, and 
NAC on MRP1 by means of functional ﬂ  ow cytometry in 
immortalized human bronchial epithelial cells.
Methods
Chemicals, media, and reagents
Bovine serum albumin (BSA, fraction V), minimal essen-
tial medium (MEM, supplemented with Earle’s salts and 
L-glutamine) and RPMI 1640 medium (supplemented 
with 25 mM Hepes and L-glutamine) were purchased from 
Invitrogen Life Technologies (Breda, The Netherlands). 
Carboxyﬂ  uorescein diacetate (CFDA), ipratropium bro-
mide, NAC and propidium iodide (PI) were obtained 
from Sigma-Aldrich BV (Zwijndrecht, The Netherlands). 
Budesonide (Pulmicort) was obtained from AstraZeneca BV 
(Zoetermeer, The Netherlands), formoterol fumarate dihy-
drate from Astra Draco AB (Lund, Sweden), ethylenedinitrilo 
tetraacetic acid disodiumsalt dihydrate (EDTA) from Merck 
(Darmstadt, Germany), fetal calf serum (FCS) from Bodinco 
BV (Alkmaar, The Netherlands), Vitrogen from Nutacon 
(Leimuiden, The Netherlands), and MK571 from Omnilabo 
(Breda, The Netherlands).
Bronchial cells
The human bronchial epithelial cell line 16HBE14o-, 
immortalized with pSVori- plasmid transfection, was kindly 
provided by Dr. DC Gruenert (California Paciﬁ  c Medical 
Center Research institute; San Francisco, CA) (Cozens et al 
1994). This cell line expresses MRP1 at relatively moderate 
levels. Cells were cultured in MEM supplemented with 
10% heat inactivated FCS. Before trypsinization, cells were 
washed twice with phosphate buffered saline (PBS: 6.4 mM 
Na2HPO4, 1.5 mM KH2PO4, 0.14 mM NaCl, 2.7 mM KCl, 
pH = 7.4) with 0.5 mM EDTA. 16HBE14o- cells were grown 
on tissue culture plastics coated with Vitrogen (30 μg/mL) 
and BSA (10 μg/mL).
Flow cytometry
To determine MRP1-mediated transport, cells were incubated 
with 0.1 μM CFDA as described previously (van der Kolk 
et al 1998) with slight modiﬁ  cations. CFDA is intracellularly 
converted to carboxyﬂ  uorescein (CF) which is a ﬂ  uorescent 
MRP1 substrate. To establish the effect of COPD drugs on 
MRP1-mediated activity, 1 × 106 cells were incubated in 
0.5 mL RPMI 1640 medium without FCS (37 °C, 5% CO2) 
with CFDA and with or without the addition of drugs for 
1 hour. MK571 (20 μM) was used as a positive control for 
inhibition of MRP1 activity (van der Kolk et al 1998) and 
always showed strong inhibition (more than 10-fold) of 
MRP1-mediated efﬂ  ux of CF. Budesonide and formoterol 
were added in concentrations of 10−8 M to 10−4 M. These 
drugs were dissolved in 96% ethanol and dimethyl sulf-
oxide (DMSO), respectively. In part of the experiments, 
cells were simultaneously incubated with budesonide and 
formoterol. When budesonide and formoterol are combined 
in one inhaler (eg, Symbicort®, AstraZeneca), the budesonide 
concentration is ∼18- to 35-fold higher than the concentration 
of formoterol; therefore we added concentrations of either 
drug with a comparable proportion. Ipratropium bromide was 
added in concentrations from 10−7 M to 2 × 10–4 M and NAC 
from 10–4 M to 1.6 × 10–3 M and these drugs were dissolved 
in PBS and water respectively.
Cells were pelleted for 15 seconds at 12,000 g and 
resuspended in ice-cold RPMI medium without FCS. Drug 
or MK571 was added a second time in appropriate concentra-
tions for 1 hour, this time without substrate CFDA (37 °C, 
5% CO2). After pelleting, cells were put on ice to stop efﬂ  ux 
of substrate and were resuspended in 350 μL RPMI medium 
with 0.1 μg/mL PI to distinguish dead from living cells.
Fluorescence of CF was analyzed with a FACSCaliburTM 
flow cytometer (Becton Dickinson Medical Systems; International Journal of COPD 2008:3(3) 471
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Franklin Lakes, NY, USA). We measured 10,000 events per 
sample (living cells). The Winlist 5.1 program (Verity Soft-
ware House Inc.; Topsham, ME, USA) was used to calculate 
mean ﬂ  uorescence intensity (MFI) values. All measurements 
were corrected for the negative control (medium alone) and 
for incubation with the solvents 96% ethanol and DMSO if 
appropriate. The percentage of dead cells (PI positive popu-
lation) did not increase with all tested drug concentrations. 
None of the tested drugs caused autoﬂ  uorescence (ﬂ  uores-
cence without CFDA and PI incubation).
Statistical analysis
Data are expressed as the mean ± standard error of the mean 
(SEM). All means were calculated from 3 to 6 independent 
experiments. The paired Student’s t-test (two-tailed) was 
used to calculate modulating effects of the drug under study 
compared to control. Differences were considered signiﬁ  cant 
when p  0.05. Statistical analyses were performed with 
SPSS 12 (SPSS Inc.; Chicago, IL).
Results
Modulating effect of budesonide and 
formoterol on MRP1-mediated activity
Budesonide increased the accumulation of CF at concentra-
tions of 10–5 M and 10–4 M with 26% and 97%, respectively. 
Lower concentrations did not affect CF accumulation signiﬁ  -
cantly (Figure 1A). Formoterol had a small yet signiﬁ  cant 
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Figure 1 Modulation of MRP1-mediated activity with increasing concentrations of (A) budesonide or (B) formoterol. Dashed line indicates the MFI level of the control 
(incubation with vehicle). Data are shown of mean ± SEM of 3–4 independent experiments for budesonide and 5–6 independent experiments for formoterol. *p  0.05 
compared with control.
Abbreviations: CF, carboxyﬂ  uorescein; MFI, mean ﬂ  uorescence intensity; MRP1, multidrug resistance-associated protein 1.International Journal of COPD 2008:3(3) 472
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effect on the accumulation of CF at 10–8 M, but at higher 
concentrations this effect was not signiﬁ  cant (Figure 1B).
COPD patients are often treated with a combined therapy 
of budesonide and formoterol. To address the question 
whether the effect of budesonide is altered by addition 
of formoterol, we incubated the highest concentration of 
budesonide (10–4 M) with increasing concentrations of for-
moterol. With this approach, the budesonide-induced CF 
accumulation decreased in a dose-dependent manner; with 
10–6 M, 10–5 M, and 10–4 M formoterol, respectively, 198%, 
124%, and 58% compared with the control (Figure 2).
Modulating effect of ipratropium bromide 
and N-acetylcysteine on MRP1-mediated 
activity
Ipratropium bromide increased CF accumulation at relatively 
low concentrations (10–7 M to 10–5 M) with a maximum of 24% 
at 10−7 M (Figure 3A). Increasing the concentration of ipratro-
pium bromide to 2 × 10–4 M potentiated the CF efﬂ  ux (56% 
compared with control), suggesting that MRP1-mediated activ-
ity is stimulated rather than inhibited with ipratropium bromide. 
Similar results were obtained with NAC, ie, CF accumulation 
was reduced in a concentration-dependent manner (57% at 8 × 
10–4 M) (Figure 3B). Increasing the NAC concentrations to 
1.6 × 10–3 M potentiated the CF efﬂ  ux even more.
Discussion
The membrane protein MRP1 is highly expressed in human 
lung tissue and may protect the airways against damage 
induced by cigarette smoking (Scheffer et al 2002). This 
study shows for the ﬁ  rst time the direct inﬂ  uence of pul-
monary drugs on MRP1 functional activity, drugs that have 
already proven their effectiveness in the clinical management 
of COPD.
Since MRP1 function is most likely cytoprotective in 
lung cells, we argued that modulation of its function with 
pulmonary drugs might induce either a positive or negative 
effect in COPD with long-term treatment. We observed that 
budesonide interfered with MRP1-mediated transport by 
increasing CF retention. This implies either that budesonide 
is an MRP1 substrate or that it acts on MRP1 function in 
another way. Budesonide is intracellularly esteriﬁ  ed to a fatty 
acid which is thought to be the mechanism of its prolonged 
activity after a single dose (O’Connell 2003). MRP1 has 
been shown to be capable of rather slow outward transport 
of phospholipids, phophatidylcholine and sphingomyelin, 
and phospholipid analogues in the presence of oxidized glu-
tathione and ATP in human erythrocytes and epithelial cells 
(Dekkers et al 2000). It is tempting to speculate that esteriﬁ  ed 
budesonide could behave like a phospholipid analogue with 
a polar head and two fatty acid tails and is then outwards 
transported by MRP1. As such, budesonide can compete 
with other MRP1 (physiological) substrates and in that way 
affect the functional activity of MRP1.
We measured the direct effect of budesonide on 
MRP1-mediated transport. In addition, budesonide is 
also able to affect the transcriptional regulation of MRP1, 
as shown by diminished expression of MRP1 in the lung 
epithelial cell line Calu-1 after long-term incubation with 
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Figure 2 Modulation of MRP1 activity by budesonide, formoterol, or their combination. Dashed line indicates the MFI level of the control (incubation with vehicle). Data are 
shown of mean ± SEM of 3 independent experiments. *p  0.05 compared with control.
Abbreviations: CF, carboxyﬂ  uorescein; MFI, mean ﬂ  uorescence intensity; MRP1, multidrug resistance-associated protein 1.International Journal of COPD 2008:3(3) 473
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budesonide (10–5 M) (Bandi and Kompella 2002). Taken 
together, the data suggest that treatment with budesonide 
could potentially have a negative effect in COPD, given 
the cell protective properties of MRP1. Our observation 
does not distract from the well known beneﬁ  cial effects of 
budesonide in diseases like asthma, since steroids suppress 
virtually every step of the inﬂ  ammatory cascade. However, 
our ﬁ  ndings may contribute an alternative hypothesis why 
inhaled steroids are not capable of altering the long-term 
course of COPD, particularly in smokers with COPD 
(Alsaeedi et al 2002).
In combination with formoterol, the direct inhibitory 
effect of budesonide on CF accumulation of epithelial cells 
was reduced, whereas formoterol as such had only minor 
effects on MRP1-mediated transport. This indicates that 
budesonide or its esteriﬁ  ed derivatives is less available 
as an MRP1 substrate/inhibitor when combined with 
formoterol or that formoterol interferes with the interac-
tion between budesonide (esters) and MRP1. Although 
formoterol is moderately lipophilic, it has a high afﬁ  nity 
for cellular membrane lipid bilayers (Anderson et al 1994). 
High concentrations of formoterol might interfere with the 
function of membrane proteins as this depends on the lipid 
environment of the protein. The effect with formoterol may 
also indirectly run via adenosine 3',5'-cyclic monophosphate 
(cAMP) since formoterol stimulates cells via the beta(2)-
adrenergic receptor (Johnson and Rennard 2001) resulting 
in higher intracellular levels of cAMP. However, it is not 
clear why this occurs in the presence of budesonide while 
formoterol alone had no effect.
Ipratropium bromide incubation resulted in lower 
CF retentions with increasing concentrations in a 
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Figure 3 Modulation of MRP1-mediated activity with increasing concentrations of (A) ipratropium bromide or (B) N-acetylcysteine. Dashed line indicates the MFI level of 
the control (incubation with vehicle). Data are shown of mean ± SEM of independent experiments for ipratropium bromide (n = 5 for 10–7 to 10–4 M; n = 1 for 2 × 10–4 M), 
and for N-acetylcysteine (n = 3–6 for 1 × 10–4 to 8 × 10–4 M; n = 1 for 1.6 × 10–3 M). *p  0.05 compared with control.
Abbreviations: CF, carboxyﬂ  uorescein; MFI, mean ﬂ  uorescence intensity; MRP1, multidrug resistance-associated protein 1.International Journal of COPD 2008:3(3) 474
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concentration-dependent manner. Ipratropium bromide 
competitively inhibits acetylcholine binding to the musca-
rinic receptor resulting in decreased guanosine 3',5'-cyclic 
monophosphate (cGMP) levels which lowers broncho-
constriction. There are no reports in the literature on its 
mechanism of action with respect to MRP1, but it can be 
speculated that cGMP might play a role in this process since 
cGMP is a substrate of other members of the MRP family, 
MRP4 and MRP5 (Wielinga et al 2003).
Effects of NAC were similar to those observed with 
ipratropium bromide, ie, MRP1-mediated transport was 
stimulated with increasing concentrations of NAC. This 
may be due to the fact that NAC elevates glutathione levels. 
Glutathione and many glutathione conjugates are substrates 
for MRP1, and therefore, intracellular glutathione levels 
are of major importance for MRP1 function in antioxidant 
defense. It is known that transport of anionic species such 
as CF can be stimulated with glutathione (Akan et al 2005; 
Bagrij et al 2001). It was observed that the compounds 
sulﬁ  npyrazone and indomethacin stimulate glutathione 
transport by MRP2 at low concentrations, whereas rela-
tively high concentrations inhibit GSH transport into the 
medium (Evers et al 2000). A possible explanation was 
given that both compounds are transported cooperatively. 
Our results with NAC and ipratropium bromide might be 
explained by a similar co-transport of these substances 
with CF. It may occur that certain (at present undeﬁ  ned) 
toxic inhaled substances can be transported by MRP1 more 
effectively with increasing glutathione levels as well. For 
example, the tobacco-derived NNAL-O-glucuronide was 
identiﬁ  ed as an MRP1 substrate that requires glutathione 
for transport (Leslie et al 2001).
The pulmonary drugs that we tested are, apart from 
NAC, clinically administered by inhalation. These drugs 
act directly on epithelial cells or pass the epithelial layer 
and act on eg smooth muscle cells or inﬂ  ammatory cells. 
Clinically achievable concentrations at the level of airway 
epithelium are mainly unknown. The intracellular levels 
that can be reached with treatment highly depend on the 
biochemical features of the substance, action of drug 
metabolism proteins (phase II conjugation enzymes such as 
cytochrome P450 isoforms), drug efﬂ  ux pumps (phase III 
systems), as well as the route of administration. We have 
chosen the ranges of the applied drug concentrations based 
on published data (Gustafsson and Persson 1991; Anderson 
et al 1994; Gillissen et al 1997; Nagy et al 1997; Bandi 
and Kompella 2002; Borchard et al 2002) and theoretical 
models, ie, ranges that will be clinically effective. MRP1 
is located in bronchial epithelium, the ﬁ  rst cells that drugs 
have to encounter to reach the underlying tissue to act 
on eg smooth muscle cells, ﬁ  broblasts and inﬂ  ammatory 
cells. Thus, local high cellular concentrations of pulmonary 
drugs are very likely to affect MRP1 activity in bronchial 
epithelium which was indeed conﬁ  rmed in vitro in the 
present study.
In conclusion, our studies show that drugs that are 
clinically used in COPD affect MRP1 function, a transporter 
that protects against oxidative stress and toxic compounds. 
Budesonide inhibits this MRP1-mediated transport and 
addition of formoterol on its turn reduces this inhibitory effect 
whereas ipratropium bromide and NAC stimulate MRP1 
activity in a concentration-dependent manner. Further studies 
are required to investigate whether stimulation of MRP1 
activity is beneﬁ  cial for long-term treatment of COPD with 
regard to the protective properties of MRP1.
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